Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials

Figures & data

Table 1. Two independent sample proportional comparison.

	Only HIV excluded in %			Only Hep B&C excluded in %			HIV & Hep B&C excluded in%
	Yes	No		Yes	No		Yes	No
Academic vs Industry	43.7	56.3	OR = 0.7474 p = 0.0242	34.1	65.9	OR = 0.7169 p = 0.0127	31.4	68.6	OR = 0.7625 p = 0.0469
	50.9	49.1		41.9	58.1		37.5	62.5
Academic vs Research org	43.7	56.3	OR = 0.8851 p = 0.3436	34.1	65.9	OR = 0.8412 p = 0.1969	31.4	68.6	OR = 0.8526 p = 0.2435
	46.7	53.3		38.0	62.0		34.9	65.1
Academic vs NCI/NIH	43.7	56.3	OR = 1.0978 p = 0.6835	34.1	65.9	OR = 0.9870 p = 0.9561	31.4	68.6	OR = 1.2183 p = 0.4320
	41.4	58.6		34.3	65.7		27.3	72.7
Industry vs Research Org	50.9	49.1	OR = 1.1843 p = 0.1157	41.9	58.1	OR = 1.1736 p = 0.1446	37.5	62.5	OR = 1.1182 p = 0.3175
	46.7	53.3		38.0	62.0		34.9	65.1
Industry vs NCI/NIH	50.9	49.1	OR = 1.4688 p = 0.0763	41.9	58.1	OR = 2.0257 p = 0.1547	37.5	62.5	OR = 1.5978 p = 0.0484
	41.4	58.6		34.3	65.7		27.3	72.7
Research Org vs NCI/NIH	46.7	53.3	OR = 01.2403 p = 0.3211	38.0	62.0	OR = 1.1732 p = 0.4781	34.9	65.1	OR = 1.4290 p = 0.1338
	41.4	58.6		34.3	65.7		27.3	72.7

Figure 1. Trend of HIV and Hep B&C exclusions in clinical trials over time.